Company Description
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.
It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E.
Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996.
The company was incorporated in 1996 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 1996 |
| IPO Date | Feb 19, 2004 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 408 |
| CEO | Ryan Spencer |
Contact Details
Address: 2100 Powell Street, Suite 720 Emeryville, California 94608 United States | |
| Phone | (510) 848-5100 |
| Website | dynavax.com |
Stock Details
| Ticker Symbol | DVAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001029142 |
| CUSIP Number | 268158201 |
| ISIN Number | US2681582019 |
| Employer ID | 33-0728374 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ryan Spencer | Chief Executive Officer, Interim Chief Financial Officer and Director |
| David F. Novack | President and Chief Operating Officer |
| Dr. Robert Janssen | Chief Medical Officer and Senior Vice President of Clinical Development, Medical and Regulatory Affairs |
| Kelly MacDonald | SVice President and Chief Financial Officer (Leave of Absence) |
| Justin Burgess | Principal Accounting Officer and Controller |
| Jeff P. Coon | CHRO and Senior Vice President of Human Resources and Administration |
| Paul Cox | Vice President of Investor Relations and Corporate Communications |
| John Slebir | Senior Vice President and General Counsel |
| Donn Casale | Chief Commercial Officer |
| Dr. Dong Yu | Senior Vice President of Vaccine Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | ARS | Filing |
| Apr 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 12, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 144 | Filing |
| Feb 22, 2024 | 10-K | Annual Report |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |